Trapidil attenuates diabetic cardiomyopathy via GPX3/Nrf2-mediated inhibition of myocardial pyroptosis
BackgroundCurrently, there is a paucity of clinically effective medications for the treatment of diabetic cardiomyopathy (DCM), while the strategy of drug repurposing offers a promising avenue for advancing therapeutic development.MethodsThe investigation explored the ameliorative effects and uncove...
Guardat en:
| Autors principals: | , , , , , , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Frontiers Media S.A.
2025-06-01
|
| Col·lecció: | Frontiers in Pharmacology |
| Matèries: | |
| Accés en línia: | https://www.frontiersin.org/articles/10.3389/fphar.2025.1566622/full |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|